By Tarun Sai Lomte Reviewed by Lauren Hardaker May 4 2026 A landmark clinical trial reveals that a widely used obesity drug may also curb alcohol cravings and consumption, opening a potential new front in addiction treatment.  Study: Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial . Image credit: Pietukhova/Shutterstock.com In a recent study published in  The Lancet , researchers investigated